Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil; Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario K7L 3N6, Canada.
Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario K7L 3N6, Canada.
Ageing Res Rev. 2016 Mar;26:112-4. doi: 10.1016/j.arr.2016.01.006. Epub 2016 Jan 30.
A major impediment to the development of safe and effective therapeutics in Alzheimer's disease (AD) lies in difficulties in translating research findings across species: therapies that work in rodents often do not translate to humans. A route to bridge the gap between promising rodent research and the human clinical condition consists in using non-human primates (NHPs), which are phylogenetically much closer to humans. In this article, we discuss the importance of investigating disease mechanisms from cell culture, through different animal models of disease. We highlight that developing a viable, validated NHP AD model will likely be a key step toward understanding AD-relevant pathogenic mechanisms and for developing therapies that will effectively translate to the human disease condition.
阿尔茨海默病(AD)治疗方法的安全性和有效性的发展主要面临一个障碍,即难以在物种间转化研究结果:在啮齿动物中有效的疗法通常不能转化到人类身上。一种弥合有前景的啮齿动物研究与人类临床状况之间差距的途径是使用与人类在进化上更为接近的非人类灵长类动物(NHPs)。在本文中,我们讨论了从细胞培养到不同疾病动物模型研究疾病机制的重要性。我们强调,开发可行的、经过验证的 AD 非人类灵长类动物模型很可能是理解 AD 相关致病机制和开发有效转化为人类疾病状况的治疗方法的关键步骤。